Overview
US ophthalmic device maker's preliminary Q2 sales are approximately $27 mln
Company faced commercial headwinds in Q2, including more widespread competitive trialing
2026 sales guidance lowered, gross margin outlook raised
Outlook
RxSight now sees 2026 sales of $110 mln-$120 mln, down from $120 mln-$135 mln prior guidance
Company raises 2026 gross margin outlook to 73%-75% from previous 70%-72%
RxSight expects 2026 operating expense at high-end of $150 mln-$160 mln range, in line with previous guidance
Result Drivers
COMPETITIVE PRESSURE - Co said more widespread competitive trialing created commercial headwinds in Q2
LAL SALES - Sales included 24,917 Light Adjustable Lens units and 11 Light Delivery Devices
COLLABORATION REVENUE - Q2 prelim revenue included $5 to $7 mln from Alcon strategic collaboration
Company press release:
Key Details
Metric Q2 Prelim Sales | Beat/Miss | Actual $27 mln | Consensus Estimate |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Rxsight Inc is $9.00, about 60.4% above its July 2 closing price of $5.61
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .